Justin J. Noznesky
Net Worth

Last updated:

What is Justin J. Noznesky net worth?

The estimated net worth of Mr. Justin J. Noznesky is at least $9,982,684 as of 1 May 2024. He owns shares worth $2,530,582 as insider, has earned $4,159,442 from insider trading and has received compensation worth at least $3,292,660 in AtriCure, Inc..

What is the salary of Justin J. Noznesky?

Mr. Justin J. Noznesky salary is $470,380 per year as Chief Marketing & Strategy Officer in AtriCure, Inc..

How old is Justin J. Noznesky?

Mr. Justin J. Noznesky is 47 years old, born in 1978.

What stocks does Justin J. Noznesky currently own?

As insider, Mr. Justin J. Noznesky owns shares in one company:

Company Title Shares Price per share Total value
AtriCure, Inc. (ATRC) Chief Marketing & Strategy Officer 71,284 $35.5 $2,530,582

What does AtriCure, Inc. do?

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Justin J. Noznesky insider trading

AtriCure, Inc.

Mr. Justin J. Noznesky has made 16 insider trades between 2018-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,500 units of ATRC stock worth $36,135 on 1 May 2024.

The largest trade he's ever made was exercising 29,134 units of ATRC stock on 2 Jan 2020. As of 1 May 2024 he still owns at least 71,284 units of ATRC stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 1,500 $24.09 $36,135
Sale
Common Stock 1,500 $30.39 $45,585
Sale
Common Stock 1,500 $36.72 $55,080
Sale
Common Stock 4,119 $80 $329,520
Sale
Common Stock 21,000 $47.33 $993,930
Option
Stock Option (right to buy) 15,000 $18.3 $274,500
Option
Common Stock 15,000 $18.3 $274,500
Sale
Common Stock 23,397 N/A N/A
Option
Stock Option (Right to Buy) 15,000 N/A N/A
Option
Common Stock 15,000 N/A N/A
Sale
Common Stock 23,397 N/A N/A
Sale
Common Stock 10,000 $40 $400,000
Sale
Common Stock 10,000 $35 $350,000
Sale
Common Stock 29,134 $25.6 $745,685
Option
Common Stock 15,000 $18.3 $274,500
Option
Stock Option (right to buy) 15,000 $18.3 $274,500
Sale
Common Stock 10,000 $30 $300,000
Option
Common Stock 15,000 $18.3 $274,500
Option
Stock Option (right to buy) 15,000 $18.3 $274,500
Sale
Common Stock 15,000 $18.3 $274,500
Sale
Common Stock 12,569 $27.64 $347,407
Sale
Common Stock 4,000 $30.32 $121,280
Sale
Common Stock 4,000 $23.05 $92,200
Sale
Common Stock 4,000 $17.03 $68,120

AtriCure key executives

AtriCure, Inc. executives and other stock owners filed with the SEC: